U.S. markets close in 3 hours 47 minutes
  • S&P 500

    4,533.45
    -2.74 (-0.06%)
     
  • Dow 30

    35,478.88
    -130.46 (-0.37%)
     
  • Nasdaq

    15,160.29
    +38.61 (+0.26%)
     
  • Russell 2000

    2,287.37
    -2.40 (-0.10%)
     
  • Crude Oil

    81.33
    -2.09 (-2.51%)
     
  • Gold

    1,783.90
    -1.00 (-0.06%)
     
  • Silver

    24.22
    -0.23 (-0.92%)
     
  • EUR/USD

    1.1640
    -0.0012 (-0.10%)
     
  • 10-Yr Bond

    1.6650
    +0.0290 (+1.77%)
     
  • GBP/USD

    1.3802
    -0.0023 (-0.17%)
     
  • USD/JPY

    113.7750
    -0.5540 (-0.48%)
     
  • BTC-USD

    63,203.71
    -3,454.77 (-5.18%)
     
  • CMC Crypto 200

    1,498.09
    -36.55 (-2.38%)
     
  • FTSE 100

    7,190.30
    -32.80 (-0.45%)
     
  • Nikkei 225

    28,708.58
    -546.97 (-1.87%)
     

PeptiDream Inks $2.2B Deal To Broaden Alnylam's siRNA Delivery Scope

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and PeptiDream Inc have announced a license and collaboration agreement to discover and develop peptide-siRNA conjugates to deliver RNAi therapeutics to tissues outside the liver.

  • Under the alliance, Alnylam will pick out a set of receptors, and PeptiDream will tailor-make a peptide for each. Alnylam will then generate peptide-siRNA conjugates and conduct the studies needed to decide which peptide to use for drug candidates.

  • Under the terms of the agreement, PeptiDream will receive an upfront payment from Alnylam as well as R&D funding.

  • PeptiDream may also receive milestone payments up to $2.2 billion.

  • In addition, PeptiDream is eligible to receive low-to-mid single-digit royalties on sales on any such Alnylam products.

  • Price Action: ALNY shares closed at $181.83 on Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.